Brayton Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 03-01-2025
- Paid Up Capital ₹ 0.10 M
as on 03-01-2025
- Company Age 12 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 3.59%
(FY 2020)
- Profit -12.43%
(FY 2020)
- Ebitda -0.77%
(FY 2020)
- Net Worth 42.75%
(FY 2020)
- Total Assets 21.99%
(FY 2020)
About Brayton Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Hiral Parikh, Rekhaben Patel, Darshak Patel, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24239GJ2012PTC070037
- Company No.
070037
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Apr 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Brayton Pharmaceuticals?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Darshana Patel  | Director | 11-Mar-2016 | Current |
| Hiral Parikh | Director | 23-Apr-2012 | Current |
| Rekhaben Patel | Director | 23-Apr-2012 | Current |
| Darshak Patel | Director | 23-Apr-2012 | Current |
| Anandiben Patel | Director | 11-Mar-2016 | Current |
| Sagar Patel | Director | 22-Mar-2019 | Current |
Financial Performance of Brayton Pharmaceuticals.
Brayton Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 3.59% increase. The company also saw a substantial fall in profitability, with a 12.43% decrease in profit. The company's net worth Soared by an impressive increase of 42.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Brayton Pharmaceuticals?
In 2020, Brayton Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nuciphar Healthcare Private LimitedActive 1 year 5 monthsSagar Patel and Vishrut Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Brayton Pharmaceuticals?
Unlock and access historical data on people associated with Brayton Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Brayton Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Brayton Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
